Found 49 Solid Tumors trials
A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
UPCC 06922: A First-in-Human Open-label Dose-escalation Trial with Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects with Malignant Solid Tumors
Please refer to Section 3 of the full protocol (Objectives and Endpoints) Please refer to Section 3 of the full protocol (Objectives and Endpoints) Please refer to Section 3 of the full protocol (Objectives and Endpoints)
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, andAnti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected SolidTumors
To evaluate an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors. A personalized vaccine, consisting of between 4 to 20 synthetic long peptides, will be generated for each patient and shall be administered as an adjuvanted vaccine, with the adjuvant Hiltonol.
UPCC 26921: A Phase 1a/1b Open-label Dose-Escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination with Pembrolizumab in Subjects with Solid Tumors
Please refer to Section 4 of the full protocol (Study Objectives and Endpoints) Please refer to Section 4 of the full protocol (Study Objectives and Endpoints) Please refer to Section 4 of the full protocol (Study Objectives and Endpoints)
A Study to Evaluate the Efficacy and Safety of Belzutifan Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)
This is a study to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET). The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST …
A Phase 1 Open-Label Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Multi-center, open-label, first in human (FIH) Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CARTTnMUC1 cells). …
UPCC 38922: A Phase I Multicenter Open-label First-in Human Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors
Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints)
UPCC 29922: First-in-human open-label multicenter Phase I/IIa dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumors
Please refer to Protocol BNT142-01, section 1.1 Trial synopsis, Objectives and endpoints. Please refer to Protocol BNT142-01, section 1.1 Trial synopsis, Objectives and endpoints. Please refer to Protocol BNT142-01, section 1.1 Trial synopsis, Secondary objectives.
UPCC 52422: A Phase 1 Multicenter Open-Label Dose-Escalation and Expansion Study to Evaluate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas Large Granular Lymphocytic Leukemia and Solid Tumors
Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints)
Please choose between Voice or SMS based delivery of verification code
or